Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Nexalin Technology, Inc. ( (NXL) ) is now available.
On February 24, 2026, Nexalin Technology, Inc. announced it is advancing a pivotal clinical trial of its HALO Clarity device for moderate to severe insomnia, in a randomized, triple-blinded, sham-controlled study of at least 150 U.S. patients. The fully decentralized trial, run via the company’s NeuroCare virtual clinic and in collaboration with Lindus Health, is designed to back a planned de novo submission for a non-pharmacological insomnia therapy.
The study builds on earlier peer-reviewed insomnia data and international approvals of Nexalin’s 15 mA DIFS devices, underscoring its push into the multi-billion-dollar insomnia market. By targeting deeper brain structures associated with sleep regulation and leveraging a patient-centric virtual model, Nexalin aims to strengthen its regulatory footing and expand its DIFS platform across high-prevalence neuropsychiatric conditions.
The most recent analyst rating on (NXL) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Nexalin Technology, Inc. stock, see the NXL Stock Forecast page.
More about Nexalin Technology, Inc.
Nexalin Technology, Inc. is a neurotechnology company that designs and develops non-invasive neurostimulation medical devices aimed at treating mental health disorders. Its Deep Intracranial Frequency Stimulation platform and Gen-2 15 mA devices, already approved in markets including China, Brazil, Oman and Israel, target deeper brain structures to address conditions such as insomnia.
The company focuses on bioelectronic, drug-free therapies for high-prevalence neuropsychiatric indications, positioning its HALO Clarity device and virtual NeuroCare clinic to serve large, underserved patient populations. Nexalin is pursuing a global strategy to strengthen clinical and regulatory foundations for broader commercialization across multiple mental health indications.
Average Trading Volume: 328,731
Technical Sentiment Signal: Sell
Current Market Cap: $10.52M
Find detailed analytics on NXL stock on TipRanks’ Stock Analysis page.